Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS views and news. Opt-in with us: www.register.msviewsandnews.org


~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.


Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

=================================================


Friday, April 20, 2018

Mylan Inks Deal with Mapi Pharma for Multiple Sclerosis Drug

 By Zacks Equity Research, 

Shutterstock photo
Mylan N.V. MYL announced that it has inked an agreement with Israel-based Mapi Pharma Ltd.
Both companies have teamed up for the development and commercialization of GA Depot, a long-acting Glatiramer Acetate product. Mylan also acquired the global marketing rights of the product.
We note that GA Depot is a proposed once-monthly injection for the treatment of patients with relapsing-remitting multiple sclerosis ("MS"), or RRMS. Mapi Pharma has completed an open-label phase II trial. The company is also preparing to commence phase III trials to support marketing applications. Both companies are preparing to submit an investigational new drug application to the FDA, as well as other global health authorities.
We remind investors that Mylan already has experience in the Glatiramer Acetate market.
In October 2017, Mylan launched the generic version of Teva's TEVA Copaxone 40 mg/mL which is indicated for the treatment of patients with relapsing forms of MS. Mylan's partner in Europe, Synthon, also received marketing authorization approval in Europe for Glatiramer Acetate Injection 40 mg/mL.
An estimated 2.3 million people on a worldwide basis are living with MS. Nearly 1 million people are living with MS in the United States. RRMS accounts for approximately 85% of initial MS diagnoses.  
The deal with Mapi Pharma will further strengthen the company's presence in the MS market.

Keep up to date with MS news and views:

SUBSCRIBE to our MS Learning Channel on YouTube: 
                       www.youtube.com/msviewsandnews





No comments: